Replies to post #182906 on Biotech Values

[DewDiligence]

It’s a little worrisome that MRK speaks so little about MK-8931.

[DewDiligence]

VTAE +30% AH on phase-1 data for BACE inhibitor:

http://www.fiercebiotech.com/story/boehringer-vitae-survive-first-clinical-challenge-crowded-alzheimers-race/2014-10-23

This program is partnered with Boehringer Ingelheim.

[DewDiligence]

VTAE -23% AH on safety halt for B-I’s BACE drug:

http://finance.yahoo.com/news/bace-inhibitor-bi-1181181-voluntarily-211000710.html

Vitae Pharmaceuticals, Inc. today announced that its partner Boehringer Ingelheim has voluntarily placed BI 1181181 on a temporary clinical hold, and has notified regulatory agencies of its decision. BI 1181181 is an orally-active beta secretase (BACE) inhibitor being evaluated in Phase 1 clinical trials for the treatment and prevention of Alzheimer's disease. This action was taken to further investigate skin reactions observed in some study participants during the multiple rising dose trial.

Note: VTAE (Vitae) should not be confused with the recent IPO, NVTA (Invitae).